Martin MacKay

Martin MacKay

Fondateur chez RALLYBIO CORPORATION

Fortune : 6 M $ au 31/08/2026

69 ans
Health Technology
Commercial Services
Technology Services

Profil

Dr. Martin W.
MacKay
is a Chairman at Rallybio Corp., a Chairman at Charles River Laboratories International, Inc., a Chief Executive Officer at Calyx Group Ltd. (Ireland), a Chief Executive Officer & Director at Rallybio Holdings LLC and an Independent Director at Charles River Laboratories, Inc. He is on the Board of Directors at Kailera Therapeutics, Inc., Rallybio Holdings LLC and Charles River Laboratories, Inc. Dr. MacKay was previously employed as an Independent Director by Springworks Therapeutics, Inc., an Independent Director by 5:01 Acquisition Corp., an Independent Director by Novo Nordisk A/S, a Senior Advisor by New Leaf Venture Partners LLC, a Chairman by Rallybio LLC, a Global Head-Research & Development by Alexion Pharmaceuticals, Inc., a Chief Executive Officer & Director by Neverfail, Inc., a President-Global Research & Development by AstraZeneca PLC, a President by Pfizer (St. Louis), a Senior Vice President-Worldwide Development by Pfizer Inc., a Head-Molecular & Cell Biology by CNS Research Institute P.C., a Head-Drug Preformulation & Delivery by Ciba-Geigy Pharmaceuticals, a Principal by Accenture LLC, a Head-Drug Preformulation & Delivery by BASF Performance Products Ltd. (United Kingdom), a Principal by Beecham Pharmaceuticals (UK), a Chief Executive Officer & Director by Neverfail Ltd., a Director-Business Development by NorthgateArinso, Inc., a Principal by PeopleSoft USA, Inc., an Operations Director by The Dun & Bradstreet Corp., a Chief Executive Officer by Vecta Software Corp.
Ltd., and a Vice President-International by VeriSign, Inc. He also served on the board at Encysive Pharmaceuticals, Inc. He received his undergraduate degree from Heriot-Watt University and a doctorate degree from The University of Edinburgh.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
08/05/2026 17 137 ( 0,04 % ) 5 M $ 31/08/2026
18/02/2026 91 818 ( 1,73 % ) 2 M $ 31/08/2026

Postes actifs de Martin MacKay

SociétésPosteDébut
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Président 05/05/2026
RALLYBIO CORPORATION Fondateur 01/01/2018
Directeur/Membre du Conseil -
Directeur Général -
Directeur Général 22/12/2010

Anciens postes connus de Martin MacKay

SociétésPosteFin
NOVO NORDISK A/S Directeur/Membre du Conseil 14/11/2025
SPRINGWORKS THERAPEUTICS, INC. Directeur/Membre du Conseil 01/07/2025
501 ACQU Directeur/Membre du Conseil 22/04/2022
ALEXION PHARMACEUTICALS, INC. Directeur Technique/Scientifique/R&D 01/06/2017
░░░░░░░░░░░ ░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Martin MacKay

Formation de Martin MacKay

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

93

Relations au 1er degré

29

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées29

Health Technology

Health Technology

Health Technology

Health Technology

Technology Services

Commercial Services

Technology Services

Commercial Services

Health Technology

Communications

Process Industries

Consumer Services

Consumer Services

Technology Services

Finance

Health Technology

Commercial Services

Commercial Services

Technology Services

Commercial Services

Technology Services

Commercial Services

Ciba-Geigy Pharmaceuticals

Beecham Pharmaceuticals (UK)

Commercial Services

Health Services

Health Technology

Finance

Health Technology

  1. Bourse
  2. Insiders
  3. Martin MacKay
🔇